SHARE

France, Innovation, 2017

Telomium continues to develop their product

15th July 2019

Telomium, one of the winners of the French Innovation Journey from Education to Business

After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.

After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group

Annika Szabo Portela appointed MD EIT Health Scandinavia

Annika Szabo Portela appointed MD EIT Health Scandinavia

Meet EIT Health Scandinavia's new MD

Find out more

EIT Health-supported Limula raises €4.7M

EIT Health-supported Limula raises €4.7M

Find out more about the EIC Pathfinder grant

Find out more

42 start-ups through to Catapult 2022-23 semifinals

42 start-ups through to Catapult 2022-23 semifinals

Discover the promising start-ups chosen

Find out more